Furthermore, it also inhibits the metastatic behavior of the human prostate cancer cells by inhibiting cell adhesion, invasion, and invasion, by downregulating of the expression of the CAV1, NR2F1, PLAU, and IGF2 genes and suppressing the secretion of urokinase plasminogen activator (Jiang et al., 2011). This evidence concerns the gene PLAU and prostate carcinoma.